HLA分型及其在个体化肿瘤肽疫苗中的应用  

HLA classification and its application in individualized peptide vaccines

作　　者：杜娟[1] 陈仿军[1] 李雷[1] 刘宝瑞[1] 

机构地区：[1]南京大学医学院附属鼓楼医院肿瘤中心,江苏南京210008

出　　处：《现代肿瘤医学》2016年第3期480-482,共3页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81172094;81172281);南京市科技计划项目(编号:201303001)

摘　　要：恶性肿瘤临床治疗已经进入肿瘤综合性治疗和个体化治疗的时代,肿瘤免疫治疗也是目前肿瘤治疗研究的热点之一,尤其是个体化肿瘤肽疫苗已成为肿瘤治疗的一种新思路。人类白细胞抗原(HLA)分子和抗原决定簇的良好结合是个体化肿瘤肽疫苗、肿瘤肽刺激的树突状细胞瘤苗及体外培养后回输的抗原特异性T细胞能否产生抗肿瘤免疫作用的关键因素。本文介绍了HLA与个体化肿瘤肽疫苗的关系并分析目前HLA相关的个体化肿瘤肽疫苗的临床研究情况及我国人群HLA分布。The clinical treatment of malignant tumor has entered the era of comprehensive treatment and individual ized therapy. Immunotherapy is one of the hot topics of tumor therapy, especially the individualized peptide vaccine has become a new way of cancer treatment. Good binding of human leukoeyte antigen（HLA） molecules and antigenic determinants is a key factor in the development of anti - tumor immune function of peptide vaccine, peptide impulsed dendritic cell vaecine and the antigen specific T cells cultured in vitro. In this paper, the relationship between HLA and individual peptide vaccine is introduced. The clinical research of HLA related peptide vaccine and the distribution of HLA in China are also analyzed.

关 键 词：人类白细胞抗原(HLA) 个体化 肽疫苗 肿瘤 

分 类 号：R730.51[医药卫生—肿瘤]